ClinicalTrials.gg

Program

LY03020

A development code.

Its studies are mostly in Schizophrenia, led by Luye Pharma Group.

Furthest: phase 2, since Feb 2, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Luye Pharma Group43 open or runningphase 2since Feb 2, 2026Aug 13, 2024Dec 31, 2027phase 2 · NCT07396870

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 13, 2024First study: phase 1 study in SchizophreniaFirst studyNCT06556966 · 66 enrolled · China
  2. Aug 6, 20252 phase 1 studies in SchizophreniaNCT07292233, NCT07230652
  3. Feb 2, 2026Phase 2 study in SchizophreniaPhase 2 reachedNCT07396870 · 160 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in SchizophreniaNCT07396870

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07396870Schizophrenia · China2Not yet recruitingDec 31, 2027160
NCT07292233Schizophrenia · China1Active, not recruitingAug 27, 202516
NCT07230652Schizophrenia · China1RecruitingDec 31, 202540
NCT06556966Schizophrenia · China1CompletedFeb 13, 202566

How it is read

Names in the registry

  • “LY03020”, 4 entries

Codes read as this program: LY03020.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.